Melanomas are considered to be one of the most immunogenic cancers and are frequently infiltrated with CD8^+^ and CD4^+^ T lymphocytes specific for major tumor antigens. CD8^+^ cytotoxic T lymphocytes (CTL) mediate antigen-specific lysis of tumor cells through cytolytic granule proteins, such as granzymes, granulysin, and perforin. Previously, other investigators have shown a lack of complete CTL differentiation in solid tumors.[@R1] However, the exact stage of differentiation affected was unclear. We recently reported in *Clinical Cancer Research* a novel subset of CD8^+^ tumor-infiltrating lymphocytes (TILs) that co-expressed early effector-memory markers (CD27, CD28) and a marker for end-stage, senescent T cells (CD57).[@R2]

CD28 and CD27 are markers of early CD8^+^ effector-memory T (T~EM~) cells. Based on studies on virus-specific T cells in humans, it was postulated that CD8^+^ T~EM~ cells differentiate in a linear pathway from CD28^+^CD27^+^ (early-differentiated) to CD28^-^CD27^+^ (intermediate-differentiated) to CD28^-^CD27^-^ (late-differentiated).[@R3] As CD8^+^ T~EM~ transitions to end-stage effector (T~EFF~), the loss of CD28 and gain of CD57 is an immunological characteristic of humans and non-human primates, but not of mice.[@R3] CD57 is a marker on highly differentiated CD8^+^CD27^-^CD28^-^ T cells needed to control CMV and other endemic viruses in humans.[@R3]^,^[@R4] CD57 was also proposed as a marker of end-stage, senescent CD8^+^ T cells in HIV patients exhibiting highly cytotoxic potential.[@R3]^,^[@R5] However, in HIV progressors, a failure to coordinately downregulate CD27 and upregulate CD57 resulted in an accumulation of an unusual subset of HIV-specific CD8^+^CD27^+^CD57^+^ cells.[@R4] CD8^+^CD27^+^CD57^+^ T lymphocytes have also been observed in the peripheral blood of melanoma patients after vaccination with gp100 tumor antigen.[@R6]

We set out to determine the role of CD8^+^CD57^+^ T cells in the melanoma. By performing flow cytometry staining on TIL isolated from 44 metastatic tumors, we found that the CD8^+^CD57^+^ subset was 16.2 ± 3.5% of the total tumor-infiltrating CD8^+^ T cells. The vast majority of these CD8^+^ T cells were also "locked" in the T~EM~ stage and, on average, \> 20% of the CD8^+^CD57^+^ subset co-expressed CD27 and CD28. These T cells were GB^hi^ but Perf^lo/-^, and they recognized melanoma tumor antigens, MART-1 and gp100 in HLA-A2^+^ patients. In contrast, only a few (\< 5%) of the CD8^+^CD57^+^ T cells in the PBMC of the same melanoma patients co-expressed CD27 and CD28, but they were GB^hi^ and Perf^hi^. We also found a similar population in pleural effusions from metastatic breast cancer. Notably, this TIL subset was different from the Foxp3^+^ CD8^+^ early effector TILs, which did not express CD57, as reported earlier.[@R7]

Whether CD8^+^CD57^+^ T cells are really "senescent" has become a controversial issue.[@R3] We addressed this issue in the CD8^+^CD27^+^CD57^+^ TIL subset and found that they indeed proliferated in response to IL-2. We then purified this subset from IL-2-cultured TILs by cell sorting. Interestingly, we found that the CD27^+^CD57^+^ TILs were able to proliferate and produce high levels of IFN-γ upon TCR stimulation, which was inconsistent with CD57 as a general marker for T-cell senescence. We also found that PD-1 expression was higher in the CD27^+^CD57^+^ subset compared with the CD27^+^CD57^-^ subset. Since CD8^+^ T cells naturally express PD-1 as a result of TCR activation, where it plays a regulatory mechanism to prevent over-reactivity,[@R3] it is possible that the CD8^+^CD27^+^CD57^+^ subset are more highly activated T cells in the tumor microenvironment.

Building on our observation that CD8^+^CD57^+^ TILs were non-senescent, we hypothesized that these T cells were in a transition state and could be induced to differentiate further to cytotoxic end-stage effectors. Indeed, we found that the sorted CD8^+^CD27^+^CD57^+^ TILs, which were Perf^lo^ and poorly cytotoxic, could differentiate into a Perf^hi^, highly cytotoxic CD27^-^CD57^+^ or CD27^-^CD57^-^ subset after TCR stimulation ([Fig. 1](#F1){ref-type="fig"}). IL-2 treatment alone induced a minor fraction of CD27^+^ precursor cells to become CD27^+^CD57^+^, which suggested that IL-2 was sufficient to expand the CD27^+^CD57^+^ subset from CD27^+^ precursors ([Fig. 1](#F1){ref-type="fig"}). TCR-stimulation induced the differentiation of sorted CD8^+^CD27^+^CD57^-^ TILs into a Perf^hi^, CD27^-^CD57^-^ subset, but the cells differentiating from the CD27^+^CD57^+^ subset on average acquire higher perforin levels and killing function ([Fig 1](#F1){ref-type="fig"}). We also found that TGF-β1, produced by many melanomas, arrested the differentiation and cytotoxic activities of both the CD27^+^CD57^-^ and CD27^+^CD57^+^ subsets at the CD27^+^ stage. Taken together, these findings may help explain why metastatic melanomas are often infiltrated with only early T~EM~ CD8^+^ T cells that have limited ability to kill tumor cells. Thus, TGF-β1 may be a key suppressor of CTL differentiation in the tumor microenvironment. However, other factors such as PGE~2~, indoleamine 2,3-diooxygenase (IDO), IL-10, or inhibitory signaling through PD-1, may also play a role.[@R8]

![**Figure 1.** Differentiation pathway of the tumor-infiltrating CD8^+^ T cells in metastatic cancer. In situations where CD8^+^ T cells encounter persistent, chronic antigenic stimulation such as metastatic cancer or uncontrolled chronic viral infections, CD8^+^ effector-memory T (T~EM~) cells fail to coordinate downregulation of CD27 with upregulation of an end-stage CTL marker, CD57 and acquire a more cytolytic phenotype. Thus T~EM~ fail to transition from a granzyme B (GB^+^) perforin^lo^ (Perf^lo^) cells into Perf^hi^, highly cytotoxic end-stage CTL. This resulted in accumulation of CD8^+^ T cells at a transitional stage where markers for early T~EM~ (CD27, CD28) are co-expressed with CD57, even though the cells remain Perf^lo^. We also found that TGF-β1, an immunosuppressive cytokine frequently found in the microenvironment of metastatic cancer, could also contribute to the arrested differentiation and accumulation of CD27^+^CD57^-^ precursor T cells and CD27^+^CD57^+^ T cells. We found that PD-1 was expressed more in the CD27^+^CD57^+^ T cells, which implied that they may exhibit a higher level of effector activity. When these tumor-infiltrating lymphocytes (TIL) are expanded with IL-2, a minor fraction (\~30%) of CD27^+^CD57^-^ subset differentiated into CD27^+^CD57^+^ T cells. After TCR stimulation ex vivo, the CD27^+^CD28^+^CD57^-^ subset directly differentiated to become CD27^-^CD57^-^ T cells. On the other hand, CD27^+^CD57^+^ differentiated to become CD27^-^CD57^+^, and, in some patients, CD27^-^CD57^-^. These phenotypic changes were accompanied by increased perforin expression and acquisition of potent cytotoxicity against tumor cells. We think that CD57 is not a marker for T-cell senescence, but rather marks highly differentiated T cells that are in the process of transitioning into a truly end-stage, effector CTL. Currently it is not known which set of markers define truly senescent, end-stage, highly cytolytic CTL. We also propose that ultimately, both the CD8^+^CD57^+^ and CD8^+^CD57^-^ subsets may ultimately differentiate into a subset of CD8^+^CD27^-^CD28^-^CD57^-^ cells that may be more NK-like, expressing higher levels of CD122, KLRG1, NKG2D and other NK receptors.](onci-1-954-g1){#F1}

Another interesting observation we made was that both the CD8^+^CD27^+^CD57^+^ and CD8^+^CD27^+^CD57^-^ T cells seemed to ultimately differentiate into CD27^-^CD57^-^ (also CD28^-^) cells subset with high perforin and killing activity. Are these the true end-stage or terminally-differentiated state of CTL that actually may be more NK-like, by expressing CD122, other NK receptors (NKG2D and high KIR levels)? These cells have been described before, but their origin is unknown.[@R9]

In conclusion, we characterized a novel subset of TILs in metastatic melanoma and breast cancer that seems to be locked in a transitional state between early T~EM~ and fully-differentiated CTL. Our study also underscores the need for a greater understanding of the state of CTL differentiation and activity in patients in relation to tumor control. Overall, there has been an over-emphasis on the role of cytokine release by CD8^+^ T cells (e.g., IFNγ), which has generally not correlated with clinical efficacy during cancer immunotherapy. A case in point is the recent HIV vaccine trials where effective immunization correlated more with a gain of antigen-specific CTL phenotype and killing function rather than IFN-γ production.[@R10]
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